Herwig Schüler

Herwig Schüler

Affiliated to Research | Docent
Visiting address: Blickagången 16, 14151 Flemingsberg
Postal address: H7 Medicin, Huddinge, H7 Bionut Avdelningsgemensamt, 171 77 Stockholm
Part of:

About me

  • Undergraduate studies in Frankfurt, Uppsala and Stockholm. Doctorate in cell
    biology from Stockholm University. Postdoctoral studies in biochemistry at
    New York University Medical Center. Group leader at KI since 2008 (2008 Team
    leader, Structural Genomics Consortium, MBB
  • 2011, independent group leader,
    MBB
  • 2018 BioNut). Associate Professor (docent) in structural biology 2013.
    Chairman for Vetenskapsrådet review panel NT-9, 2017, 2018.

Research

  • Posttranslational modifications (PTMs) orchestrate many vital events in
    cells, including the remodeling of chromatin in gene activation and
    inactivation, the transcription of active genes, the repair of damaged DNA,
    and the interaction of proteins in cellular signaling networks. Many enzymes
    are involved in putting these PTM marks in the right place at the right time,
    and in removing them in the proper context. Specific binder domains are
    involved in their recognition. Because of the consequences of their actions
    and because they can often be inhibited by small compounds, these proteins
    are often targets for drug development. With small compounds that act on
    these proteins we can, for instance, kill cancer cells, or influence
    signaling processes to reach a therapeutic outcome. This requires that we
    understand the actions of both the target proteins and the inhibitor
    substances to great detail in order for the therapeutic agents to be
    effective and safe.
    We are interested to understand to atomic detail how the PTM
    ADP-ribosylation functions. For that, we study the 3-dimensional structures
    of PARP and related enzymes with ADP-ribosyltransferase activity, and
    determine their enzymatic properties. We also collaborate with chemists to
    develop more portent and more selective PARP inhibitors. We study the binder
    domains that recognize ADP-ribosylation marks in the cell. Finally, we study
    bacterial toxins that catalyze the same reaction, with the aim to devise
    novel anti-infectives.

Articles

All other publications

Employments

  • Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2024-2024
  • Affiliated to Research, Department of Biosciences and Nutrition, Karolinska Institutet, 2023-2024

Degrees and Education

  • Docent, Karolinska Institutet, 2013

News from KI

Events from KI